|
1
|
Lech A, Daneva T, Pashova S, et al:
Ovarian cancer as a genetic disease. Front Biosci (Landmark Ed).
18:543–563. 2013. View
Article : Google Scholar
|
|
2
|
Pruthi S, Gostout BS and Lindor NM:
Identification and management of women with BRCA mutations or
hereditary predisposition for breast and ovarian cancer. Mayo Clin
Proc. 85:1111–1120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Werner H and Bruchim I: IGF-1 and BRCA1
signalling pathways in familial cancer. Lancet Oncol. 13:e537–e544.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Samani AA, Yakar S, LeRoith D and Brodt P:
The role of the IGF system in cancer growth and metastasis:
overview and recent insights. Endocr Rev. 28:20–47. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bruchim I and Werner H: Targeting IGF-1
signaling pathways in gynecologic malignancies. Expert Opin Ther
Targets. 17:307–320. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pfäffle R, Kiess W and Klammt J:
Downstream insulin-like growth factor. Endocr Dev. 23:42–51.
2012.
|
|
7
|
Scully R: Histological Typing of Ovarian
Tumours. 9. 2nd edition. Springer; Berlin, Germany: 1999,
View Article : Google Scholar
|
|
8
|
Bi FF, Li D and Yang Q: Promoter
hypomethylation, especially around the E26 transformation-specific
motif, and increased expression of poly (ADP-ribose) polymerase 1
in BRCA-mutated serous ovarian cancer. BMC Cancer. 13:902013.
View Article : Google Scholar
|
|
9
|
Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson
JL, Wilbanks GD, Burke F and Balkwill FR: Expression and regulation
of tumor necrosis factor alpha in normal and malignant ovarian
epithelium. Mol Cancer Ther. 5:382–390. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Varley KE, Gertz J, Bowling KM, et al:
Dynamic DNA methylation across diverse human cell lines and
tissues. Genome Res. 23:555–567. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hudelist G, Wagner T, Rosner M, et al:
Intratumoral IGF-I protein expression is selectively upregulated in
breast cancer patients with BRCA1/2 mutations. Endocr Relat Cancer.
14:1053–1062. 2007. View Article : Google Scholar
|
|
12
|
Maor S, Yosepovich A, Papa MZ, Yarden RI,
Mayer D, Friedman E and Werner H: Elevated insulin-like growth
factor-I receptor (IGF-IR) levels in primary breast tumors
associated with BRCA1 mutations. Cancer Lett. 257:236–243. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen X, Meng Q, Zhao Y, et al: Angiotensin
II type 1 receptor antagonists inhibit cell proliferation and
angiogenesis in breast cancer. Cancer Lett. 328:318–324. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calvo V and Beato M: BRCA1 counteracts
progesterone action by ubiquitination leading to progesterone
receptor degradation and epigenetic silencing of target promoters.
Cancer Res. 71:3422–3431. 2011. View Article : Google Scholar
|
|
15
|
Katiyar P, Ma Y, Riegel A, Fan S and Rosen
EM: Mechanism of BRCA1-mediated inhibition of progesterone receptor
transcriptional activity. Mol Endocrinol. 23:1135–1146. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ansquer Y, Legrand A, Bringuier AF, Vadrot
N, Lardeux B, Mandelbrot L and Feldmann G: Progesterone induces
BRCA1 mRNA decrease, cell cycle alterations and apoptosis in the
MCF7 breast cancer cell line. Anticancer Res. 25:243–248.
2005.PubMed/NCBI
|
|
17
|
Ma Y, Fan S, Hu C, et al: BRCA1 regulates
acetylation and ubiquitination of estrogen receptor-alpha. Mol
Endocrinol. 24:76–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma Y, Hu C, Riegel AT, Fan S and Rosen EM:
Growth factor signaling pathways modulate BRCA1 repression of
estrogen receptor-alpha activity. Mol Endocrinol. 21:1905–1923.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ingle JN, Liu M, Wickerham DL, et al:
Selective estrogen receptor modulators and pharmacogenomic
variation in ZNF423 regulation of BRCA1 expression: individualized
breast cancer prevention. Cancer Discov. 3:812–825. 2013.
View Article : Google Scholar
|
|
20
|
Nelson AC, Lyons TR, Young CD, Hansen KC,
Anderson SM and Holt JT: AKT regulates BRCA1 stability in response
to hormone signaling. Mol Cell Endocrinol. 319:129–142. 2010.
View Article : Google Scholar : PubMed/NCBI
|
